Cerebral Blood Flow Measurement of MRI using PSO17 in Normal Subjects

Cerebral Blood Flow Measurement of MRI using PSO17 in Normal Subjects - Cerebral Blood Flow Measurement using PSO17

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029935

Enrollment

Registered

2017-11-16

Start date

2017-11-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain infarction, brain tumor, epilepsy

Interventions

intravenous administration of PSO17 and arterial blood collection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) healthy Japanese (20 - 65 years old) (2) body weight < 80 kg (3) informed consent is obtained

Exclusion criteria

Exclusion criteria: (1)metallic implant or claustrophobia (2)blood flow abnormality by Allen test (3)chronic disorders (4)CNS, liver, kidney or heart disease (5)acute infection before 30 days (6)drug allergy (7)chronic intake of drugs (> 30 days) (8)other clinical trial within 90 days (9)willing to have babies or during breast feeding

Design outcomes

Primary

Measure	Time frame
Correlation of PSO17 concentrations between calculated by MRI signals and of arterial blood sampling	—

Secondary

Measure	Time frame
1) Qualitative comparison of PSO17 concentrations calculated by MR signals and of arterial blood sampling 2) vital signs (blood pressure, heart rate, and body temperature) 3) adverse effect	—

Countries

Japan

Contacts

Public ContactKohsuke Kudo

Hokkaido University Hospital department of diagnostic and interventional radiology

kkudo@huhp.hokudai.ac.jp011-706-7779

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026